US Capitol Capsule: Improving The Biosimilars Review Process: What's Needed?
This article was originally published in Scrip
As the FDA gets ready to embark on the reauthorization process for the next round of the Biosimilar User Fee Act (BsUFA), which permits the agency to collect user fees from industry to aid in the reviews of biosimilars applications, known as 351(k)s, it wants to hear stakeholders' thoughts at a Dec. 18 public meeting on how well regulators are completing their program goals so far and what should be retained, changed or discontinued to improve performance.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.